Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study | Zendy

Jannik HelwegLarsen | Zendy; Thomas Benfield | Zendy; Chiara Atzori | Zendy; Robert F. Miller | Zendy

Open Access

Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study

Author(s) -

Jannik HelwegLarsen,

Thomas Benfield,

Chiara Atzori,

Robert F. Miller

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp372

Subject(s) - pentamidine , primaquine , medicine , trimethoprim , dapsone , pneumocystis pneumonia , sulfamethoxazole , clindamycin , pneumocystis jirovecii , hazard ratio , pneumonia , surgery , confidence interval , immunology , antibiotics , microbiology and biotechnology , malaria , biology , chloroquine

First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research